Indivior Pharmaceuticals, Inc.

addiction treatment and CNS pharmaceuticals

INDV · Nasdaq · United States

Share price · INDV

$36.28-1.09 (-2.92%) 3M

no price since 2 Nov 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when INDV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Aug 2026+6.1%

    Nothing announced by INDV that day or the session before.

  2. 3 Aug 2026-6.6%
  3. 30 Apr 2026+7.7%
  4. 23 Feb 2026-2.8%
  5. 3 Nov 2025+6.2%

Share of unusual movement by asset

For each asset, the share of INDV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
buprenorphine extended-release (SUBLOCADE)
events and moves
86%
nalmefene nasal spray (OPVEE)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—65%
Sessions with no dated event—29%

Assets

(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
Mu-opioid receptor (partial agonist)Small molecule
Substance Use Disorder
Opioid Use Disorder
Approved
Opioid receptorSmall molecule
Substance Use Disorder
Opioid Overdose Reversal
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 February 2025Approvalbuprenorphine extended-releaseFDA approves SUBLOCADE label changes (rapid initiation, alternative injection sites)
US, FDA · Source ↗

Financial reports

Quarterly & interim (10)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$356M$5.0M$305M—$97M operating cash flowreport ↗
View 9 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$343M$12M$222M—$229M operating cash flowreport ↗
2026-Q1$317M$16M$175M—-$9.0M operating cash flowreport ↗
2025-Q3$314M$33M$445M+ $0 short-term inv.—-$39M operating cash flowreport ↗
2025-Q2$302M$21M$510M+ $0 short-term inv.—$158M operating cash flowreport ↗
2025-Q1$266M$22M$372M+ $1.0M short-term inv.—$75M operating cash flowreport ↗
2024-Q4——$319M+ $1.0M short-term inv.—-$17M operating cash flowreport ↗
2024-Q3$307M$22M$288M—$2.0M operating cash flowreport ↗
2024-Q2$299M$26M$302M$97M$88M operating cash flowreport ↗
2024-Q1$284M$28M$248M—-$37M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.2B$97M$195M+ $0 short-term inv.—-$27M operating cash flowreport ↗

For FY2025, the company reported revenue of $1,239M, up 4.3% YoY, with R&D spend of $97M, down 9.3% YoY. Cash and equivalents were $195M, and the company recorded GAAP net income of $210M.

The company reaffirmed its full-year 2026 guidance of net revenue of $1,125M to $1,195M, total SUBLOCADE net revenue of $905M to $945M, non-GAAP operating expenses of $430M to $450M, and adjusted EBITDA of $535M to $575M. Key disclosed events included the launch of a nationwide direct-to-consumer campaign, conclusion of the legacy DOJ matter with a $295M payment, completion of the redomiciliation to the U.S., entry into Phase II of the Indivior Action Agenda Accelerate, and authorization of a new $400M share repurchase program.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.2B$107M$319M+ $1.0M short-term inv.—$36M operating cash flowreport ↗
2023-FY$1.1B$116M$316M+ $94M short-term inv.$32M-$300M operating cash flowreport ↗
2022-FY$901M$74M$774M$11M-$4.0M operating cash flowreport ↗
2021-FY——$1.1B—report ↗

Insider transactions

Open-market activity, trailing 12 months: 10 purchases ($312K), 3 sales ($2.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Rubin Jonathan · SVP, Chief Medical OfficerOther (see filing)21,529——Form 4
2026-11-02Khattar Jack A. · director, Chief Executive OfficerOther (see filing)1,937,986——Form 4
2026-11-02GEMAYEL GEORGES · directorOther (see filing)42,009——Form 4
2026-11-02Sensenig Bethany · directorOther (see filing) (derivative)4,603——Form 4
2026-11-02Bhatt Padmanabh P. · SVP of IP, CSOOther (see filing)28,702——Form 4
2026-11-02Barlow Carrolee · directorOther (see filing)41,652——Form 4
2026-11-02DEC TIMOTHY C · SVP, Chief Financial OfficerOther (see filing)14,059——Form 4
2026-11-02Horich William Todd · SVP, Chief Commercial OfficerOther (see filing) (derivative)20,021——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 287 reporting institutions held 127.5M shares ($3.8B, 108.0% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.18,542,220$565.2M
2VANGUARD PORTFOLIO MANAGEMENT LLC7,891,819$240.5M
3OAKTREE CAPITAL MANAGEMENT LP6,984,102$212.9M
4VANGUARD CAPITAL MANAGEMENT LLC5,586,576$170.3M
5STATE STREET CORP4,903,993$149.5M
6Two Seas Capital LP4,746,510$144.7M
7MILLENNIUM MANAGEMENT LLC4,595,535$140.1M
8FULLER & THALER ASSET MANAGEMENT, INC.4,529,583$138.1M
9Madison Avenue Partners, LP4,315,162$131.5M
10CITADEL ADVISORS LLC3,574,044$108.9M
11MORGAN STANLEY3,505,817$106.9M
12DEERFIELD MANAGEMENT COMPANY, L.P.3,097,790$94.4M
13GEODE CAPITAL MANAGEMENT, LLC2,925,688$89.2M
14MANGROVE PARTNERS IM, LLC2,742,434$83.6M
15GOLDMAN SACHS GROUP INC2,409,165$73.4M